Diabetic retinopathy, a leading cause of vision loss affecting millions, damages the retina's blood vessels. Experts ...

Take Ken, a man from Reno who is living a full life at an age when most people would be long retired. Eleven years ago – at age 77 – he began working as an usher at a luxury movie theater. As a movie ...

This article is authored by Dr Subrata Dutta, director, Regional Institute of Ophthalmology, Kolkata.

That’s exactly what happened after a 2018 Federal Court decision that redefined “anaesthetic services” – and taxpayers are ...

Ocular Therapeutix shifts Axpaxli's approval strategy, raising valuation risks and regulatory uncertainty. Click here to read ...

ANI’s FutureVision Advisory Council is co-led by Arshad M. Khanani, MD, MA, FASRS, who serves as Principal Retina Advisor and Chair, and Peter Chang, MD, FACS who serves as Principal Uveitis Advisor ...

Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive ...

Chugai Pharma announces 48-week NIHONBASHI phase III study results presented at JRVS meeting show that Vabysmo sustained vision improvements in Japanese patients with angioid streaks ...

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...

Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global ...